Get the Stockscreener App
0.302
9.03%
0.025
Cue Biopharma Inc stock is traded at $0.302, with a volume of 1.30M.
It is up +9.03% in the last 24 hours and down -26.34% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.277
Open:
$0.2803
24h Volume:
1.30M
Relative Volume:
1.55
Market Cap:
$27.55M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.3319
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
-16.23%
1M Performance:
-26.34%
6M Performance:
-64.72%
1Y Performance:
-76.41%
1-Day Range:
$0.2803
$0.3067
1-Week Range:
$0.2675
$0.37
52-Week Range:
$0.2302
$1.54
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.302 | 25.27M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Is Cue Biopharma Inc. (1UC) stock overpriced at current multiples2025 Trading Volume Trends & Growth Oriented Trading Recommendations - bollywoodhelpline.com
Cue Biopharma (NASDAQ:CUE) Shares Up 9% – Should You Buy? - Defense World
Activity Recap: Whats the profit margin of Cue Biopharma IncJuly 2025 Short Interest & Low Drawdown Momentum Ideas - baoquankhu1.vn
Analyst Upgrade: Can Cue Biopharma Inc be recession proofJuly 2025 Snapshot & Daily Growth Stock Investment Tips - baoquankhu1.vn
Cue Biopharma launches proposed public offering of shares and warrants - MSN
Can Cue Biopharma Inc. stock outperform in 2025 bull marketWeekly Investment Recap & AI Driven Price Forecasts - Улправда
How sustainable is Cue Biopharma Inc. stock dividend payout2025 Growth vs Value & Short-Term Trading Alerts - Улправда
Why Cue Biopharma Inc. stock is trending among retail tradersStock Surge & Verified Momentum Stock Ideas - Улправда
What sentiment indicators say about Cue Biopharma Inc. stock2025 Pullback Review & Reliable Momentum Entry Alerts - Улправда
Aug Big Picture: Why Cue Biopharma Inc. stock remains resilient2025 Top Gainers & Consistent Return Strategy Ideas - Улправда
Why Cue Biopharma Inc. stock remains resilientJuly 2025 Highlights & Free Safe Capital Growth Stock Tips - Улправда
Will Cue Biopharma Inc. stock see insider buyingStop Loss Placement Tips & Small Entry Cost Investments - Улправда
Institution Moves: Will Cue Biopharma Inc 1UC stock benefit from mergersTrade Risk Assessment & AI Forecast Swing Trade Picks - Bộ Nội Vụ
Is Cue Biopharma Inc. stock attractive for growth ETFs2026 world cup usa national team semifinals top scorers high defensive line tactical prediction expert opinion - Улправда
2026 world cup lineups insights: Will Cue Biopharma Inc. stock benefit from AI adoption2026 world cup usa national team round of 32 young talents transition play tactical prediction insights - ulpravda.ru
CUE Stock Price, Forecast & Analysis | CUE BIOPHARMA INC (NASDAQ:CUE) - Chartmill
EBIT per share of Cue Biopharma, Inc. – SWB:1UC - TradingView — Track All Markets
CUE Insider Trading - Quiver Quantitative
Is Cue Biopharma Inc a good long term investmentStock Screening Results & Big Gains Low Budget - earlytimes.in
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Cue Biopharma stock: niche immunotherapy bet caught in a bruising small-cap biotech storm - AD HOC NEWS
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Cue Biopharma (CUE) price target increased by 25.00% to 5.10 - MSN
Working capital per share of Cue Biopharma, Inc. – SWB:1UC - TradingView — Track All Markets
Cue Biopharma prices $10M underwritten public offering; shares down - MSN
Can Cue Biopharma Inc. stock rebound after recent weaknessTreasury Yields & Verified Swing Trading Watchlists - Улправда
How Cue Biopharma Inc. (1UC) stock reacts to stronger dollarMarket Activity Report & Risk Controlled Swing Trade Alerts - Улправда
Published on: 2025-12-20 23:54:48 - moha.gov.vn
Cue Biopharma Signs Underwriting Agreement With H.C. Wainwright & Co. - TradingView — Track All Markets
Cue Biopharma prices $10 million public offering at $0.28 per share - Investing.com Nigeria
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Cue Biopharma (CUE) Launches $10 Million Public Offering with Wa - GuruFocus
Cue Biopharma prices 35.7M shares at 28c in underwritten public offering - TipRanks
Cue Biopharma (CUE) Launches $10 Million Public Offering with Warrants - GuruFocus
Cue Biopharma announces pricing of $10 million public offering - marketscreener.com
Why retail investors pile into Cue Biopharma Inc. stock2025 Valuation Update & Safe Capital Growth Plans - ulpravda.ru
Cue Biopharma Announces Pricing of $10 Million Public Offering - GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Is Cue Biopharma Inc. (1UC) stock undervalued by metricsPortfolio Risk Report & Precise Trade Entry Recommendations - DonanımHaber
Why Cue Biopharma Inc. stock is seen as undervalued2025 Buyback Activity & Fast Gaining Stock Strategy Reports - DonanımHaber
How interest rate cuts could boost Cue Biopharma Inc. stockQuarterly Performance Summary & Daily Technical Stock Forecast Reports - DonanımHaber
Cue Biopharma launches public offering of common stock and warrants By Investing.com - Investing.com Australia
Insider Trends: Why retail investors pile into Cue Biopharma Inc. stockAnalyst Downgrade & Free High Accuracy Swing Entry Alerts - Улправда
Will Cue Biopharma Inc. stock benefit from AI adoptionQuarterly Growth Report & Free Fast Entry Momentum Trade Alerts - Улправда
Cue Biopharma (CUE) Announces Proposed Offering with Key Managers - GuruFocus
Cue Biopharma stock tumbles on public offering announcement By Investing.com - Investing.com Canada
Cue Biopharma launches public offering of common stock and warrants - Investing.com
Cue Biopharma, Inc. Announces Underwritten Public Offering of Common Stock and Warrants - Quiver Quantitative
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):